NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Eli Lilly and Company
City of Hope Medical Center
National Cancer Institute (NCI)
Hoffmann-La Roche
Duke University
Duke University
Duke University
Duke University
M.D. Anderson Cancer Center